Damage control approach to refractory neurogenic shock: a new proposal to a well-established algorithm.

IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Colombia Medica Pub Date : 2021-06-30 eCollection Date: 2021-04-01 DOI:10.25100/cm.v52i2.4800
Michael W Parra, Carlos A Ordoñez, David Mejia, Yaset Caicedo, Javier Mauricio Lobato, Oscar Javier Castro, Jose Alfonso Uribe, Fernando Velásquez
{"title":"Damage control approach to refractory neurogenic shock: a new proposal to a well-established algorithm.","authors":"Michael W Parra,&nbsp;Carlos A Ordoñez,&nbsp;David Mejia,&nbsp;Yaset Caicedo,&nbsp;Javier Mauricio Lobato,&nbsp;Oscar Javier Castro,&nbsp;Jose Alfonso Uribe,&nbsp;Fernando Velásquez","doi":"10.25100/cm.v52i2.4800","DOIUrl":null,"url":null,"abstract":"<p><p>Resuscitative endovascular balloon occlusion of the aorta (REBOA) is commonly used as an adjunct to resuscitation and bridge to definitive control of non-compressible torso hemorrhage in patients with hemorrhagic shock. It has also been performed for patients with neurogenic shock to support the central aortic pressure necessary for cerebral, coronary and spinal cord perfusion. Although volume replacement and vasopressors are the cornerstones of the management of neurogenic shock, we believe that a REBOA can be used as an adjunct in carefully selected cases to prevent prolonged hypotension and the risk of further anoxic spinal cord injury. This manuscript aims to propose a new damage control algorithmic approach to refractory neurogenic shock that includes the use of a REBOA in Zone 3. There are still unanswered questions on spinal cord perfusion and functional outcomes using a REBOA in Zone 3 in trauma patients with refractory neurogenic shock. However, we believe that its use in these case scenarios can be beneficial to the overall outcome of these patients.</p>","PeriodicalId":50667,"journal":{"name":"Colombia Medica","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/0d/1657-9534-cm-52-02-e4164800.PMC8634278.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colombia Medica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.25100/cm.v52i2.4800","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 1

Abstract

Resuscitative endovascular balloon occlusion of the aorta (REBOA) is commonly used as an adjunct to resuscitation and bridge to definitive control of non-compressible torso hemorrhage in patients with hemorrhagic shock. It has also been performed for patients with neurogenic shock to support the central aortic pressure necessary for cerebral, coronary and spinal cord perfusion. Although volume replacement and vasopressors are the cornerstones of the management of neurogenic shock, we believe that a REBOA can be used as an adjunct in carefully selected cases to prevent prolonged hypotension and the risk of further anoxic spinal cord injury. This manuscript aims to propose a new damage control algorithmic approach to refractory neurogenic shock that includes the use of a REBOA in Zone 3. There are still unanswered questions on spinal cord perfusion and functional outcomes using a REBOA in Zone 3 in trauma patients with refractory neurogenic shock. However, we believe that its use in these case scenarios can be beneficial to the overall outcome of these patients.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
难治性神经源性休克的损伤控制方法:对一种成熟算法的新建议。
在失血性休克患者中,复苏血管内球囊阻断主动脉(REBOA)通常被用作复苏的辅助手段和最终控制不可压缩性躯干出血的桥梁。它也被用于神经源性休克患者,以支持大脑、冠状动脉和脊髓灌注所需的中央主动脉压。虽然容量置换和血管加压药是治疗神经源性休克的基础,但我们认为,在精心挑选的病例中,REBOA可以作为一种辅助手段,以防止长期低血压和进一步缺氧脊髓损伤的风险。本文旨在提出一种新的损伤控制算法来治疗难治性神经源性休克,其中包括在3区使用REBOA。在顽固性神经源性休克的创伤患者中,在3区使用REBOA对脊髓灌注和功能预后仍有未解之谜。然而,我们相信在这些情况下使用它可以对这些患者的整体结果有益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Colombia Medica
Colombia Medica MEDICINE, GENERAL & INTERNAL-
CiteScore
2.00
自引率
0.00%
发文量
11
审稿时长
>12 weeks
期刊介绍: Colombia Médica is an international peer-reviewed medical journal that will consider any original contribution that advances or illuminates medical science or practice, or that educates to the journal''s’ readers.The journal is owned by a non-profit organization, Universidad del Valle, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE) and the World Association of Medical Editors (WAME) recommendations of policies on publication ethics policies for medical journals. Colombia Médica publishes original research articles, viewpoints and reviews in all areas of medical science and clinical practice. However, Colombia Médica gives the highest priority to papers on general and internal medicine, public health and primary health care.
期刊最新文献
El hilo de Ariadna en la era de la inteligencia artificial: paralelismos entre el mito griego y las recomendaciones de WAME Evidence-based practice in respiratory healthcare professionals in Latin America: Content quality and reliability of the YouTube videos about chronic prostatitis Effects of central intermittent theta-burst stimulation combined with repetitive peripheral magnetic stimulation on upper limb function in stroke patients. Artificial intelligence in scientific writing: What are the ethical boundaries? - A Reflection inspired by the myth of Prometheus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1